John J.P. Kastelein, M.D., Ph.D., Chairman, Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands, also a principal investigator for the studies, commented, "We are particularly pleased to have had such an uneventful experience with patients in the long-term study. Until now, the longest exposures to ISIS 301012 had been three months, and now to have patients dosed for a total of more than six months without any tolerability issues is quite reassuring. Of course, we will all be eager to see more patients and longer exposure times to strengthen our confidence that ISIS 301012 could truly be a transformational new drug for the treatment of refractory high cholesterol."
About ISIS 301012 and Cholesterol
ISIS 301012 is a second-generation antisense drug that reduces the
production of apoB-100, a protein critical to the synthesis and transport
of "bad" cholesterol and a target that has proved to be undruggable using
traditional, small-molecule approaches. Cholesterol can be carried in the
bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C,
being the good form, and low-density lipoproteins, or LDL-C, and very
low-density lipoproteins, or VLDL-C, being bad forms directly involved in
heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of
cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a
key component in the prevention and management of cardiovascular disease.
Isis plans to develop ISIS 301012 as the drug of choice for patients who
are unable to achieve target cholesterol levels with statins alone or who
are intolerant of statins. For future studies, including the registration
studies for FH and the
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved